Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Tivantinib Fails Phase III HCC Test

February 17th 2017

Tivantinib failed to improve overall survival compared with placebo as a second-line therapy for patients with MET-overexpressing inoperable hepatocellular carcinoma in the phase III METIV-HCC study.

Gemcitabine-Free Regimen Leads to Improved Survival in Metastatic Pancreatic Cancer

February 17th 2017

Results of the randomized phase II GERCOR trial concluded that patients with metastatic pancreatic cancer saw numerically better survival rates with a gemcitabine-free regimen when compared with a conventional gemcitabine regimen.

Response Rates Improved With Platinum Added to Nab-Paclitaxel/Gemcitabine in Advanced Pancreatic Cancer

February 16th 2017

The addition of a platinum agent to standard gemcitabine and nab-paclitaxel was found to be associated with impressive response and overall survival rates in patients with stage IV pancreatic cancer.

In MPC, Gemcitabine/Nab-Paclitaxel More Cost Effective Than With FOLFIRINOX

February 16th 2017

Real-world data presented at the 2017 Gastrointestinal Cancers Symposium demonstrated that there were significantly higher costs associated with FOLFIRINOX as first-line therapy compared with the combination of nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer.

Precision Medicine and the Future of Pancreatic Cancer

February 16th 2017

PEGPH20 in Advanced Pancreatic Cancer

February 16th 2017

The Potential for Immunotherapy in Pancreatic Cancer

February 16th 2017

Adjuvant Therapy in Pancreatic Cancer

February 16th 2017

Considerations in Locally Advanced Pancreatic Cancer

February 16th 2017

Ongoing Neoadjuvant Clinical Trials in Pancreatic Cancer

February 16th 2017

Neoadjuvant Therapy in Locally Advanced Pancreatic Cancer

February 16th 2017

Advanced Pancreatic Cancer: Quality of Life Considerations

February 16th 2017

Sequencing Decisions in Advanced Pancreatic Cancer

February 16th 2017

Liposomal Irinotecan in Advanced Pancreatic Cancer

February 16th 2017

Frontline Decisions in Metastatic Pancreatic Cancer

February 16th 2017

Metastatic Pancreatic Cancer: Dosing Strategies in the Frontline Setting

February 16th 2017

Current Practice With Molecular Testing in Pancreatic Cancer

February 16th 2017

Multidisciplinary Care in Advanced Pancreatic Cancer

February 16th 2017

Nivolumab With Nab-paclitaxel, Gemcitabine Shows Promise in Pancreatic Cancer

February 16th 2017

The combination regimen of the PD-1 inhibitor nivolumab (Opdivo) plus nab-paclitaxel and gemcitabine was found to demonstrate encouraging clinical activity and low toxicity levels in patients with metastatic pancreatic cancer.

The Future of HCC Treatment

February 15th 2017